# Oculis Holding AG (OCS)

> Source: Nexqual · https://nexqual.com/OCS · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Oculis Holding AG (OCS), nexqual.com/OCS" · informational, not investment advice.

**Price:** USD 7.4 (+3.21% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 7.17 · day 7.15–7.6 · 52w 7.11–34.48 · market cap $456M · NGM

## Key facts
- Analysts: Buy (mean 1.70 on a 1–5 scale) (10 analysts), mean target USD 36.84 (range 19.65–43.94).
- Total return with dividends: 1Y -65.7% vs S&P 500 +18.1%; 5Y -24.6% vs S&P 500 +85.1%.
- Next earnings: 2026-11-03, EPS estimate USD -0.4, revenue estimate $158K.

## Analysts
Consensus Buy (mean 1.70 on a 1–5 scale), 10 analysts; mean target USD 36.84 (low 19.65, high 43.94).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-18 | HC Wainwright & Co. | Target raised | Buy | $26 → $39 |
| 2026-08-14 | JP Morgan | Target lowered | Overweight | $23 → $20 |
| 2026-08-05 | HC Wainwright & Co. | Maintained | Buy | $26 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -65.7% | -24.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -65.8% | -5.5% |
| Volatility (annualized) | 73.3% | 54.6% |
| Max drawdown | -78.0% (May 2026→Oct 2026) | -77.3% (May 2026→Oct 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/OCS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt